Corporate News

Scientific presentations on hyperpolarized Xenon

30 July 2020

Scientific presentations on hyperpolarized 129Xenon at upcoming medical meetings

  • Polarean’s investigational drug/device lung diagnostic to be prominently featured
  • Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“129Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between 5-10 August 2020 and 8-14 August 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized 129Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, 5 August 2020:

ATS 2020 Abstract Title and Lead Author

Poster Number

Session Number

Coleman EM et al. Hyperpolarized 129Xe Identifies Ventilation Responders to Glycopyrrolate/Formoterol Furmarate in Chronic Obstructive Lung Disease



Bier EA et al. Monitoring Response to Inhaled Prostacyclin Therapy with 129Xenon MR Imaging and Spectroscopy in Patients with Pulmonary Hypertension



Neidbalski PJ et al. Hyperpolarized 129Xe MRI of Regional Capillary-Level Cardio-Pulmonary Dynamics Predict Outcomes in IPF Patients



Bier EA et al. Noninvasive Diagnosis of Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic Resonance Imaging and Spectroscopy



Mummy D et al. Hyperpolarized Xe-129 MRI Measures of Gas Exchange in Non-specific Interstitial Pneumonia



Wang Z et al. Spatial Correlation of 129Xenon Gas Exchange MRI with 99mTc Perfusion Scintigraphy



Wang Z et al. Using 129Xenon MR Gas Exchange MRI to Measure the Membrane and Capillary Components of DLCO and KCO



Mummy D et al. Hyperpolarized 129Xe MRI is sensitive to therapy response in idiopathic pulmonary fibrosis



Shim YM et al. Positive Results from Two Randomized Phase III Trials Assessing Hyperpolarized 129Xenon

Gas MRI as a Measure of Regional Lung Function as Compared to Imaging with 133Xenon Scintigraphy




Presentations of the following accepted abstracts will be delivered at ISMRM on the following days and times:

ISMRM 2020 Abstract Title and Lead Author



Session Name


Bier EA et al. Noninvasive Diagnosis of Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic

Resonance Imaging and Spectroscopy


Hyperpolarized Gas/Lung MRI

8-14 August

Mummy D et al. Hyperpolarized 129Xe MRI Measures of Gas Exchange in Non-specific Interstitial Pneumonia


Thoracic & Breast MRI

8-14 August

Niedbalski PJ et al. Imaging Regional Capillary Cardio-Pulmonary Blood Flow Dynamics using Hyperpolarized 129Xe MRI and Keyhole Reconstruction


Thoracic MRI

11 August

Rankine L et al. Quantitative dose-dependent changes in regional lung function after radiation therapy detected using xenon-129 gas exchange MRI


Thoracic MRI

11 August

Lu J et al. Bias field correction in hyperpolarized 129Xe ventilation imaging


Pulmonary Power

11 August

Wang Z et al. A model for interpreting hyperpolarized 129Xe exchange MRI


Pulmonary Power

11 August


Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM.  Session W-02 takes place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: “We are pleased to see 129Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized 129Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on 129Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”



Polarean Imaging plc
Richard Hullihen, Chief Executive Officer
Jonathan Allis, Chairman /
Via Walbrook PR

Walbrook PR
Paul McManus / Anna Dunphy

Tel: +44 (0)20 7933 8780 or [email protected]
Mob: +44 (0)7980 541 893/ +44 (0)7876 741 00

About Polarean (

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation.129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

Investor Alert

Sign up for Email Alerts